Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novartis Ag ADR
(NY:
NVS
)
102.57
-0.12 (-0.12%)
Official Closing Price
Updated: 7:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novartis Ag ADR
< Previous
1
2
3
4
5
6
7
8
9
...
26
27
Next >
Why This Regeneron Approval 'Could Not Come Soon Enough' As Novartis Looms
August 21, 2023
The FDA signed off on Regeneron's high-dose Eylea about two months earlier than expected.
Via
Investor's Business Daily
Exposures
Product Safety
SpaceX On Par With Intel, Disney; US Weight Loss Drugs Pricier; Moderna, Pfizer's Shot Effective Against New Variant: Today's Top Stories
August 18, 2023
Benzinga
Via
Benzinga
Merck Reveals Mixed Results From Pivotal Kidney Cancer Study Of Welireg In Pretreated Patients
August 18, 2023
Merck & Co Inc (NYSE: MRK) released topline results from LITESPARK-005, a Phase 3 trial investigating WELIREG (belzutifan), Merck's oral hypoxia-inducible
Via
Benzinga
Novartis' Generic Business Spinoff: Plans Sandoz Spin-Off In Early October, Proposes Share Distribution
August 18, 2023
Novartis AG (NYSE: NVS)
Via
Benzinga
2 Excellent Stocks to Buy and Hold Forever
August 17, 2023
These companies have solid long-term potential.
Via
The Motley Fool
2 Top Biotech Stocks to Buy Right Now
August 14, 2023
These drugmakers are among the most dominant in the world.
Via
The Motley Fool
Should Income Investors Buy This Blue Chip Stock?
July 23, 2023
This Swiss drugmaker is one of the most dominant players in its industry.
Via
The Motley Fool
Why Novartis Stock Spiked Today
July 18, 2023
A massive share buyback program and an improved outlook powered a mid-single-digit rise in the drugmaker's shares today.
Via
The Motley Fool
3 Unstoppable Dividend Stocks to Buy Right Now
August 12, 2023
These stocks' dividends are more dependable than most.
Via
The Motley Fool
Novartis's Remibrutinib Shows Rapid Improvement In Type Of Skin Disorder That Impacts 40M People
August 09, 2023
Novartis AG (NYSE: NVS)
Via
Benzinga
The Year’s Top 3 International ETFs as of August 2023
August 07, 2023
By investing in international ETFs, you can mitigate potential losses with a more diversified portfolio. Here are three with strong returns.
Via
InvestorPlace
3 Biotech Stocks You Better Be Buying on Each and Every Dip
July 27, 2023
Biotech companies can bring about life-changing innovations. We've created a list to help you find the best biotech stocks out there.
Via
InvestorPlace
2 Stocks That Raised Their Guidance in July
July 26, 2023
With inflation elevated, these are relatively resilient businesses to invest in.
Via
The Motley Fool
Seven Humira Biosimilars: Increased Competition In Arthritis Drug Market Sparks Need For Reform Of Drug Pricing Intermediaries
July 26, 2023
Seven pharmaceutical companies recently launched their biosimilars of AbbVie Inc's (NYSE: ABBV) top-selling
Via
Benzinga
Novartis Ag (NVS) Q2 2023 Earnings Call Transcript
July 18, 2023
NVS earnings call for the period ending June 30, 2023.
Via
The Motley Fool
Novartis Puts Up Its Biggest Earnings Growth In Two Years; Shares Pop
July 18, 2023
Novartis put up more than 17.3% growth in its profit, beating quarterly records since June 2021.
Via
Investor's Business Daily
The 7 Best Dividend Stocks to Protect Your Portfolio From Global Chaos
July 24, 2023
With global events only rising in entropy, investors ought to consider these best dividend stocks for portfolio protection.
Via
InvestorPlace
Week In Review: Novartis In $1 Billion Deal For DTx Pharma
July 22, 2023
Novartis signed a $1 billion agreement to acquire DTx Pharma, a preclinical San-Diego company developing siRNA therapies for neuroscience indications. Meanwhile, Zhuhai Biotheus formed a far-reaching...
Via
Talk Markets
Dow Jones Leads Market Advance As Tesla, Netflix, Taiwan Semiconductor Hit Growth: Weekly Review
July 21, 2023
But all the major indexes are at or near 15-month highs.
Via
Investor's Business Daily
FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt
July 21, 2023
The FDA has approved Daiichi Sankyo's (OTC: DSNKY) Vanflyta (quizartinib) in
Via
Benzinga
Earnings Preview For Novartis
July 17, 2023
Via
Benzinga
Why Harrow Health Stock Is Trading Higher Today?
July 19, 2023
Harrow Health Inc (NASDAQ: HROW) agreed to acquire the U.S. and Canadian commercial rights for Vevye (cyclosporine ophthalmic solution) 0.1%, a non‑preserved from Novaliq GmbH.
Via
Benzinga
Nasdaq Futures Rise As Focus Turns To Tesla, Netflix Q2 Prints: Analyst Says Earnings Need Some 'Heavy Lifting' For Sustained Rally
July 19, 2023
Via
Benzinga
NBCUniversal's Peacock Raises Prices First Time Since Launch, Warren Buffett Sells Majority of Activision Blizzard Stake Before Microsoft Deal Approval, Novartis Launches $15B Share Buyback: Today's Top Stories
July 18, 2023
Wall Street Journal
Via
Benzinga
Novartis Q2 Earnings: Company Lifts Outlook, Launches $15B Share Buyback, Maps Out Sandoz Spin-Off
July 18, 2023
Novartis AG (NYSE: NVS) reported Q2 FY23 sales of $13.62 billion, up 7% Y/Y and 9% on constant currency, beating the consensus
Via
Benzinga
Nasdaq, S&P 500 Futures Dip Ahead of Big Bank Earnings, Retail Sales Data: Why This Analyst Stays Cautious About Tech Sector
July 18, 2023
Via
Benzinga
Bank of America, Morgan Stanley And 3 Stocks To Watch Heading Into Tuesday
July 18, 2023
With U.S. stock futures trading slightly lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
Drug Maker Novartis Stock Shows Rising Relative Strength
July 17, 2023
Novartis stock had its Relative Strength Rating upgraded to 73 Monday -- a nice improvement, but still shy of the preferred 80-plus score.
Via
Investor's Business Daily
MoonLake's Potential Sale: Stock Price Up Fivefold Since Public Debut In 2022
July 17, 2023
MoonLake Immunotherapeutics (NASDAQ: MLTX) has reportedly engaged an investment bank as the Swiss company looks for a potential sale. The company focuses on developing antibody-derived treatments for...
Via
Benzinga
The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market
July 17, 2023
The global acute hospital care market was worth $3.2 trillion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.62% from 2023 to 2030.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
26
27
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.